prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,
priorix pdr+solv for soln for inj in a pre-filled syringe measles, mumps and rubella vaccine (live)
glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection in pre-filled syringe - mumps vaccine rit 4385 measles virus - schwarz strain rubella virus - wistar ra27/3 strain - vaccines
priorix pdr+solv for soln for inj - measles mumps and rubella vaccine (live)
glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection - measles virus - schwarz strain rubella virus - wistar ra27/3 strain mumps vaccine rit 4385 - vaccines
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccines - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vaccines - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vaccines - active immunisation against h5 subtype of influenza a virus
neovac vaccine
zoetis australia pty ltd - escherichia coli k88ac pilus antigens; escherichia coli 987p pilus antigens; escherichia coli k99 pilus antigens; escherichia coli k88ab pilus antigens; formaldehyde solution; thiomersal - misc. vaccines or anti sera - escherichia coli k88ac pilus antigens vaccine-microbial active 12.5 ug/ml; escherichia coli 987p pilus antigens vaccine-microbial active 12.5 ug/ml; escherichia coli k99 pilus antigens vaccine-microbial active 12.5 ug/ml; escherichia coli k88ab pilus antigens vaccine-microbial active 12.5 ug/ml; formaldehyde solution aldehyde other 2.5 ug/ml; thiomersal mercury other 0.15 mg/ml - immunotherapy - pig - piglet | neonatal piglet | new born pig | sucker pig - escherichia coli (e. coli) | scours - neonatal | vaccine | equine rotavirus | including b-lactamase producin
trivalent tick fever vaccine
department of agriculture and fisheries - babesia bigemina; babesia bovis; anaplasma centrale - misc. vaccines or anti sera - babesia bigemina vaccine-microbial active 0.0 p; babesia bovis vaccine-microbial active 0.0 p; anaplasma centrale vaccine-viral active 0.0 p - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - tick fever - bovine anaplasmosis | tick fever - bovine babesiosis | vaccine | anaplasma marginale | babesia bigemina | babesia bovis | equine rotavirus | red water | redwater
bivalent tick fever vaccine
department of agriculture and fisheries - babesia bovis; anaplasma centrale - misc. vaccines or anti sera - babesia bovis vaccine-microbial active 0.0 p; anaplasma centrale vaccine-viral active 0.0 p - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - tick fever - bovine anaplasmosis | tick fever - bovine babesiosis | vaccine | anaplasma marginale | babesia bigemina | babesia bovis | equine rotavirus | red water | redwater
monovalent tick fever vaccine
department of agriculture and fisheries - babesia bovis - misc. vaccines or anti sera - babesia bovis vaccine-microbial active 0.0 undefined - immunotherapy - calf | beef calf | bovine | calf - poddy | calf - preweaning | calf - sucker | dairy calf | neonatal calf - tick fever - bovine babesiosis | vaccine | babesia bigemina | babesia bovis | equine rotavirus | red water | redwater